Elucidating acquired PARP inhibitor resistance in advanced prostate cancer

George Seed; Nick Beije; Wei Yuan; Cláudia Bertan; Jane Goodall; Arian Lundberg; Matthew A. Tyler; Ines Figueiredo; Rita Pereira; Chloe Baker; Denisa Bogdan; Lewis Gallagher; Jan-Phillipp Cieslik; Semini Greening; Maryou Lambros; Rui Neves; Lorena Magraner-Pardo; Gemma Fowler; Berni Ebbs; Susana Miranda; Penny Flohr; Diletta Bianchini; Pasquale Rescigno; Núria Porta; Emma Hall; Bora Gürel; Nina Tunariu; Adam Sharp; Stephen Pettit; Nikolas H. Stoecklein; Shahneen Sandhu; David A. Quigley; Christopher J. Lord; Joaquı́n Mateo; Suzanne Carreira; Johann S. de Bono

doi:10.1016/j.ccell.2024.10.015

Related publications

Article2025

Metabolic subtyping reveals PDIK1L as a dual-functional regulator of progression and PARP inhibitor sensitivity in prostate cancer

Zhong Lin Wang, Qintao Ge, Anwaier Aihetaimujiang, Ji Zhang, Jiahe Lu, Jianfeng Yang, Yonghao Chen, Bin Qin, Hailiang Zhang, Wenhao Xu, Dingwei Ye

Article2014

Antitumour Activity of the Parp Inhibitor Olaparib in Unselected Sporadic Castration-Resistant Prostate Cancer (Crpc) in the Toparp Trial

Jane Goodall, Alexa Gillman, Helen Mossop, Christy Ralph, Zafeiris Zafeiriou, Raquel Pérez López, Nina Tunariu, Roberta Ferraldeschi, Daniel Nava Rodrigues, Lakshmi P. Kunju, Dan R. Robinson, Gerhardt Attard, Arul M. Chinnaiyan, Johann S. de Bono, Joaquı́n Mateo, Emma Hall, Shahneen Sandhu, Aurelius Omlin, Susana Miranda, Suzanne Carreira

Letter2013

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

Shahneen Sandhu, Aurelius Omlin, Lucy Hylands, Susana Miranda, Louise J. Barber, Ruth Riisnaes, Alison Reid, Gerhardt Attard, L. Chen, Iwanka Kozarewa, Heidi Gevensleben, James Campbell, Kerry Fenwick, Ioannis Assiotis, David Olmos, Timothy A. Yap, Peter C.C. Fong, Nina Tunariu, Dow‐Mu Koh, L. Rhoda Molife, S.B. Kaye, Christopher J. Lord, Alan Ashworth,

Article2019

PARP inhibitor and CX-5461 combination therapy as a novel treatment strategy for castrate-resistant prostate cancer

Laura H. Porter, Mitchell G. Lawrence, Nicholas Choo, Shahneen Sandhu, Hong Wang, David Pook, Elaine Sanij, Richard B. Pearson, Ross D. Hannan, Luc Furic, Renea A. Taylor, Gail P. Risbridger

Article2011

Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors

Johann S. de Bono, Shahneen Sandhu, Gerhardt Attard